Citizens analyst Jonathan Wolleben downgraded Astria Therapeutics (NASDAQ: ATXS) from Market Outperform to Market Perform.The analyst comments: "BioCryst is scooping ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE